Chicago Equity Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Chicago Equity Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$1.94M	Sell	19,460 -2,165	-10%	-$280K	0.2%	146
2019 Q4	$3.23M	Buy	21,625 +4,340	+25%	+$591K	0.19%	155
2019 Q3	$2.21M	Buy	17,285 +525	+3%	+$70.4K	0.11%	290
2019 Q2	$2.39M	Buy	16,760 +10,120	+152%	+$1.36M	0.11%	277
2019 Q1	$949K	Buy	6,640 +2,995	+82%	+$391K	0.04%	521
2018 Q4	$452K	Buy	+3,645	New	+$541K	0.02%	659
2014 Q2	–	Sell	-1,900	Closed	-$263K	–	477
2014 Q1	$263K	Buy	1,900 +25	+1%	+$3.76K	0.01%	401
2013 Q4	$237K	Buy	+1,875	New	+$194K	0.01%	384

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Chicago Equity Partners's JAZZ Position: Q1 2020 in Review

Chicago Equity Partners reduced its Jazz Pharmaceuticals (JAZZ) stake by 10% in Q1 2020, selling an estimated $280K and leaving 19,460 shares worth $1.94M. The position accounts for 0.2% of the portfolio, ranked #146.

Chicago Equity Partners first reported a position in JAZZ in Q4 2013 and has held it in 8 quarters since. The position peaked at $3.23M in Q4 2019. 408 funds tracked by Wall St. Rank hold JAZZ as of Q1 2020.

Chicago Equity Partners held 19,460 shares of Jazz Pharmaceuticals worth $1.94M as of Q1 2020.
Chicago Equity Partners sold 2,165 Jazz Pharmaceuticals shares in Q1 2020, an estimated $280K.
Jazz Pharmaceuticals made up 0.2% of Chicago Equity Partners's portfolio in Q1 2020, its #146 holding.
Chicago Equity Partners first reported a position in Jazz Pharmaceuticals in Q4 2013 and has held it in 8 quarters since.
Chicago Equity Partners's Jazz Pharmaceuticals position peaked at $3.23M in Q4 2019.
408 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2020.

Based on Chicago Equity Partners's 13F filing for Q1 2020, filed 6 May 2020.